Taysha Gene Therapies (TSHA) Return on Assets (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Return on Assets of 0.01% for Q1 2026, down 45.15% sequentially from 0.01% in Q4 2025, and little changed YoY from 0.01% in Q1 2025.
Taysha Gene Therapies (TSHA) Return on Assets (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Return on Assets for 7 years, with the latest figure at 0.01% in Q1 2026.
- Quarterly Return on Assets changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
- Return on Assets declined to 0.01% in Q1 2026 per TSHA's latest filing, from 0.01% in the prior quarter.
- Over five years, Return on Assets peaked at 0.01% in Q4 2025 and troughed at 0.02% in Q2 2023.
- A 5-year average of 0.01% and a median of 0.01% in 2024 frame the typical range for Return on Assets.
- The sharpest annual moves came in 2022 and 2023: Return on Assets decreased 1 bps in 2022, then rose 1 bps in 2023.
- Over 5 years, Return on Assets stood at 0.01% in 2022, then jumped by 52 bps to 0.01% in 2023, then dropped by 23 bps to 0.01% in 2024, then soared by 40 bps to 0.01% in 2025, then sank by 45 bps to 0.01% in 2026.
- According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.01% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01% |
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | -0.01% |
| Sep 30, 2023 | -0.01% |
| Jun 30, 2023 | -0.02% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | -0.01% |
| Sep 30, 2021 | -0.01% |